Novadip Biosciences to present at 20 th annual Bio€quity Europe Conference
May 16, 2019
Belgium, 16 May 2019: Novadip Biosciences (“Novadip”), a regenerative medicine company and pioneer in the development of three-dimensional tissue products derived from adipose stem cells for critical hard and soft tissue reconstruction, announces that Jeff Abbey, Chief Executive Officer, will present at the 20th Bio€quity Europe conference on 20 – 21 May 2019 in Barcelona, Spain. The presentation will take place at 15:45 CEST on Monday 20 May and will provide an update on the company’s clinical and preclinical development programs.
Bio€quity Europe has been running for 20 years, showcasing more than 800 leading European companies to thousands of investment and pharma business development professionals. Organized by BioCentury and EBD Group, the event brings together the leading investors dedicated to the European biopharmaceutical industry.
If you would like to meet with Jeff Abbey from Novadip Biosciences at the conference, please contact Jeff.email@example.com.
– Ends –
Notes to editors
Novadip Biosciences is a regenerative medicine spin-off company from Université Catholique de Louvain (UCL) and Cliniques Universitaires St-Luc founded in 2013 based on the research of Dr. Denis Dufrane. The creation of Novadip was supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II. A Series A Round of EUR 27.7 million was raised in 2015 with New Science Ventures, Fund+, SRIW, Intégrale, Epimède, VIVES II, Nivelinvest and private investors. Novadip is developing 3-dimensional tissue products derived from adipose stem cells for critical hard and soft tissue reconstruction.
For further information, please contact:
Chief Executive Officer
+32 (10) 779 220
For media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Jessica Hodgson, Angela Gray
+44 (0) 20 3709 5700
Novadip has developed a unique tissue regeneration platform capable of generating multiple product classes to transform the lives of patients with limited or no effective treatment options.